Start typing and press Enter to search

0
ALLUVI RETATRUTIDE 20MG

ALLUVI RETATRUTIDE 20MG

£139.00

A 20mg Retatrutide formulation supplied in a pre-filled research device, provided exclusively for controlled laboratory R&D applications. Delivered in sealed format to support compound stability analysis, formulation studies, and delivery mechanism evaluation. Produced for laboratory research only. Not for human or veterinary consumption.

Add to wishlistAdd to compare
SKU: ALRET20 Category:
Description

Retatrutide

Retatrutide is an experimental once-weekly injectable peptide being developed by Eli Lilly for obesity and related metabolic conditions. It is known as a “triple agonist” because it activates three receptors:

  • GLP-1: reduces appetite and slows stomach emptying.
  • GIP: supports glucose-dependent insulin release and metabolic regulation.
  • Glucagon: may increase energy expenditure and fat breakdown.

Unlike tirzepatide, which targets GLP-1 and GIP, retatrutide adds glucagon-receptor activity.

Reviews (0)

Reviews

There are no reviews yet.

Be the first to review “ALLUVI RETATRUTIDE 20MG”

Your email address will not be published. Required fields are marked *

Related Products

Start typing and press Enter to search

View more
Shopping Cart

No products in the cart.

0
0
0£0.00

Powered by
►
Necessary cookies enable essential site features like secure log-ins and consent preference adjustments. They do not store personal data.
None
►
Functional cookies support features like content sharing on social media, collecting feedback, and enabling third-party tools.
None
►
Analytical cookies track visitor interactions, providing insights on metrics like visitor count, bounce rate, and traffic sources.
None
►
Advertisement cookies deliver personalized ads based on your previous visits and analyze the effectiveness of ad campaigns.
None
Powered by